DAX25.396 +0,5%Est506.004 +0,1%MSCI World4.343 -0,1%Top 10 Crypto12,19 +1,2%Nas23.671 +0,8%Bitcoin77.643 -0,6%Euro1,1681 +0,4%Öl63,31 +0,5%Gold4.595 +1,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Deutsche Telekom 555750 Bayer BAY001 Allianz 840400 TKMS thyssenkrupp Marine Systems TKMS00 DroneShield A2DMAA Amazon 906866 BASF BASF11 RENK RENK73 Siemens Energy ENER6Y Lufthansa 823212 Volkswagen (VW) vz. 766403 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas höher -- US-Ölkonzerne vor Investments in Venezuela -- Eli Lilly plant wohl Abivax-Übernahme -- Novo Nordisk, Goldrekord, Rüstungsaktien, Amazon, DroneShield, Airbus, BYD im Fokus
Top News
Machtkampf in Washington: Fed-Chef Powell wehrt sich gegen Trumps "Einschüchterung" Machtkampf in Washington: Fed-Chef Powell wehrt sich gegen Trumps "Einschüchterung"
BYD-Aktie gefragt: E-Autobauer hat wohl neue Submarke für Fahrdienste gegründet BYD-Aktie gefragt: E-Autobauer hat wohl neue Submarke für Fahrdienste gegründet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Pacira Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
19,70 EUR -0,70 EUR -3,43 %
STU
23,53 USD -2,48 USD -9,53 %
BTT
Pacira Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.866,17 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1H68T

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6951271005

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolPCRX

Pacira Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireDOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
PR NewswireDOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
Wer­bungPacira Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireInvestors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
PR NewswireLawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation
PR NewswireDOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
PR NewswireDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswirePCRX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In PCRX To Contact Him Directly To Discuss Their Options
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswirePCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireShareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireThe Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
PR NewswireThe Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
PR NewswirePCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireInvestors who lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX
PR NewswirePacira BioSciences, Inc. Class Action: Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
PR NewswirePCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswirePCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PR NewswireDOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
PR NewswireCanadian Investment Regulatory Organization Trade Resumption - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireCanadian Investment Regulatory Organization Trading Halt - PCRX
PR NewswireDOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
PR NewswireG.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

Pacira Pharmaceuticals News

Pacira Pharmaceuticals News: auf dieser Seite finden Sie alle Pacira Pharmaceuticals News und Nachrichten zur Pacira Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pacira Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pacira Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.